Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENVAFOLIMAB in Advanced Solid Tumors
NCT04891198Phase 2Recruiting
- Sponsor
- 3D Medicines Inc.
- Start
- Aug 2021
- Primary completion
- Aug 2027
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab in solid tumor, sponsored by 3D Medicines Inc.. Started Aug 2021; status: recruiting.
02
Drugs
envafolimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04891198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04891198.